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 At present, individual techniques, including intraoperative acute normovolemic hemodilution, use of tranexamic acid,
use of intrathecal morphine, proper positioning, and modification of operative techniques, seemmost promising for
reducing perioperative blood loss and allogeneic blood transfusion in patients undergoing major spine surgery.
 Other techniques including preoperative autologous predonation; mandatory discontinuation of use of antiplatelet
agents; intraoperative and postoperative red-blood-cell salvage; use of aprotinin, epsilon-aminocaproic acid, recom-
binant factor VIIa, or desmopressin; induced hypotension; avoidance of hypothermia; andminimally invasive operative
techniques require additional studies to either establish their effectiveness or address safety considerations.
Blood loss is a major issue in spine surgery. With increased
awareness of the potential hazards of allogeneic blood transfusion,
reducing blood loss during major spine procedures becomes more
important. Achievement of this goal requires a concerted effort
from spine surgeons and anesthesiologists alike. While a prior
review of techniques to decrease blood loss during major spine
surgery has been published1, newer techniques and concepts con-
tinue to evolve rapidly in this field. The present article provides a
comprehensive review of the most recent techniques and concepts
in this area, which we have divided into those applicable in the
preoperative, intraoperative, and postoperative periods (Table I).
Preoperative Period
Optimal Management of Concurrent Medications
That May Affect Intraoperative Bleeding
Antiplatelet medications such as aspirin and clopidogrel are
commonly prescribed for patients with cardiovascular or cere-
brovascular disease. Either continuation or discontinuation of
these medications preoperatively may be associated with risks.
In ameta-analysis of 500 patients receiving aspirin on a chronic
basis, Burger et al.2 showed that withdrawal from low-dose
aspirin was the preceding event in 10.2% of patients who de-
veloped acute myocardial infarction, stroke, or peripheral ar-
terial occlusion, or who died of cardiac complications, during
non-cardiac surgery. However, continuation of aspirin use
increased the rate of intraoperative bleeding complications by
a factor of 1.5, although without a concomitant increase in
perioperative morbidity or mortality except after intracranial
surgery and transurethral prostatectomy. Hence, Burger et al.
recommended discontinuing aspirin use only if the risk of
bleeding outweighed the cardiovascular risks of aspirin with-
drawal. Chassot et al. reviewed the results of perioperative
antiplatelet therapy in patients at risk for myocardial infarction
and recommended an algorithm approach for making the
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decision to continue or discontinue use of these drugs3. The
algorithm took into account the indication for treatment as
well as the type of operation. Discontinuation of aspirin use seven
days before intracranial surgery was recommended by Chassot
et al. However, Chassot et al. recommended performing the
spine procedure without interruption of aspirin use when a
patient had had a recent myocardial infarction (less than six
weeks before the operation) or insertion of a drug-eluting stent
less than twelve months previously. Spine surgery was not
specifically addressed in the review by Burger et al.
The effect of low-dose aspirin on bleeding during spine
surgery has never been studied well. In a recent survey in which
neurosurgeons at 142 neurosurgical facilities were successfully
interviewed4, two-thirds (ninety-four) of the respondents be-
lieved aspirin to be a risk factor for hemorrhagic complications
associated with spine procedures, and more than half of the
neurosurgeons interviewed reported having personal experi-
ence of such problems during spine operations. Moreover, a
subgroup of specialists who performed more than 600 spine
operations per year thought that use of low-dose aspirin should
be discontinued seven days before the operation. In the absence
of more solid evidence, these opinions are not unreasonable.
Additional studies are needed to provide more evidence on this
subject.
Continuation of clopidogrel use by patients undergoing
non-cardiac surgery was shown to be associated with substantial
;bleeding3. Although no increase in morbidity and mortality
(except for patients treated with intracranial surgery) was found,
surgical bleeding and transfusion rates were increased by 50%.
Many orthopaedic patients may be taking nonselective cy-
clooxygenase (COX) inhibitors (nonsteroidal anti-inflammatory
drugs [NSAIDs]) preoperatively for their anti-inflammatory and
analgesic effects. These drugs have antiplatelet effects similar to
those of aspirin. However, because they are reversible COX in-
hibitors, their antiplatelet effects disappear usually over twenty-
four hours after discontinuation5. Recently, the platelet function
analyzer PFA-100 was found to be useful inmonitoring the degree
of platelet inhibition in these patients preoperatively6.
Autologous Predonation
Autologous blood predonation is an established technique that
has been reported to be safe and effective, decreasing the need
for allogeneic blood transfusion in lumbar spine fusion and
scoliosis surgery7,8. However, in a retrospective study of 676
TABLE I Outline of Techniques, and Their Strengths and Weaknesses, to Reduce Perioperative Blood Loss and Allogeneic Blood
Transfusion in Patients Undergoing Major Spine Surgery
Technique Major Strength Major Weakness/Limitation
Preoperative
Optimizing concurrent medications Insufficient evidence
Autologous predonation Safety Dubious benefit
Intraoperative
Acute normovolemic hemodilution Established efficacy Safety when combined with other
techniques unknown
Intraoperative red-blood-cell salvage Dubious benefit and cost-effectiveness
Hemostatic drugs
Antifibrinolytics
Aprotinin Thrombotic and renal complications
Tranexamic acid Established efficacy Dubious benefit
Epsilon-aminocaproic acid
Recombinant factor VIIA Safety
Desmopressin Dubious benefit
Intrathecal morphine Effective and analgesia provided Unknown mechanism of action
Controlled hypotension Safety
Maintenance of normothermia Inconclusive evidence
Surgical considerations
Patient positioning
Proper sequence of dissection
Local and topical hemostatic agents Mass effect: compression and
foreign-body reaction
Minimally invasive approach Insufficient evidence and
technical considerations
Postoperative red-blood-cell salvage Insufficient evidence
Prudent transfusion trigger Strong clinical evidence and
sound physiological basis
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patients who had undergone elective spine surgery, Brookfield
et al. reported that patients who had predonated blood had
blood loss similar to that of patients who had not predonated
and had more blood replacement9. Moreover, there was no
significant difference in allogeneic blood transfusion rates be-
tween the two groups.
A critical issue in the success of a predonation program
is the patient’s rate of erythropoiesis. Use of erythropoietin in
conjunction with an iron sulfate supplement can increase the
number of autologous blood units that the patient can donate10.
Intraoperative Period
Acute Normovolemic Hemodilution
Acute normovolemic hemodilution is widely used in spine surgery
and has had good results in terms of decreasing the allogeneic
blood transfusion requirements of patients treated with spine
fusion11,12 as well as in those treated with scoliosis surgery13,14.
Epstein et al.15 reported that allogeneic blood transfusion was
avoided by fifty-two of sixty-eight patients treated with acute
normovolemic hemodilution during lumbar spine fusion with
instrumentation. The author of an earlier review article16 con-
cluded that acute normovolemic hemodilution was both safe
and effective in decreasing the need for allogeneic blood trans-
fusion, especially in patients undergoing multilevel lumbar
laminectomies with or without fusions. One additional benefit
is that acute hemodilution of up to 30% may induce a mild hy-
percoagulable state17,18, which may help to reduce intraoperative
bleeding.
The volume of blood available for collection is determined
by the individual patient’s preoperative blood volume, hemat-
ocrit, and targeted hematocrit (estimated blood volume ·
[baseline hematocrit – targeted hematocrit]/average hematocrit)8.
There may be some difficulty with combining this technique with
autologous predonation.
Intraoperative Red-Blood-Cell Salvage
The role of intraoperative red-blood-cell salvage in reducing
the need for allogeneic blood transfusion remains controver-
sial. It was reported to be effective in reducing allogeneic blood
transfusion in spine laminectomies, fusions, or instrumenta-
tion in several retrospective studies19-21, a meta-analysis22, and a
Cochrane review23. However, the quality of these studies varies.
A recent retrospective study by Gause et al.24 showed that
the use of intraoperative red-blood-cell salvage in elective lumbar
fusion with instrumentation not only did not decrease the need
for blood transfusion, but was also associated with substantially
greater blood loss. Although the authors could not explain the
apparent paradox, they proposed that perhaps surgeons became
less meticulous with hemostasis in the presence of blood salvage.
Alternatively, the reinfused salvaged blood might have contained
products that interfered with normal coagulation.
Cost is a frequent concern about the use of intraoperative
blood salvage. The cost of red-blood-cell salvage has been shown to
exceed its benefits in patients undergoing correction for idiopathic
scoliosis13. When red-blood-cell salvage was compared with acute
normovolemic hemodilution, the latter was found to be more
cost-effective25. It has been estimated that red-blood-cell salvage is
cost-effective only if at least two blood units are recovered26.
Red-blood-cell salvage is contraindicated for surgical
procedures involving a tumor, infection, or application of some
topical agents.
Use of Hemostatic Drugs
Antifibrinolytics
Recent meta-analyses supported the usefulness of antifibrino-
lytics. A meta-analysis in 200927 showed that aprotinin and tran-
examic acid substantially reduced blood loss in pediatric scoliosis
surgery, a finding that was in agreement with that of a Cochrane
review in 200828. Another meta-analysis in 200829 also showed
tranexamic acid and epsilon-aminocaproic acid to be effective
in reducing blood loss and transfusion requirements, with no
substantial morbidity or increased rate of thromboembolic
events, in patients undergoing spine surgery.
Aprotinin
Aprotinin is a potent serine protease inhibitor extracted from
bovine lung tissues. It reduces fibrinolysis by inhibiting plas-
min activity and has been found to reduce blood loss in cardiac
surgery since 198730,31.
Aprotinin decreased blood loss and blood transfused in
patients undergoing major orthopaedic surgery that was expected
to result in blood loss of >2000mL32, but its usage in spine surgery
showed conflicting results. Previous controlled studies demon-
strated a reduction in blood loss and transfusion requirements in
adult patients undergoing spine reconstruction surgery33 and in
children and adolescents undergoing spine surgery with fusions
to correct deformity34. More recent studies also demonstrated
promising results with regard to decreasing blood loss and the
need for allogeneic blood transfusion in adults undergoing spine
surgery to correct deformity and those undergoing surgery to
address neuromuscular scoliosis35,36.
However, one randomized prospective study did not show
any reduction in blood loss in adolescents undergoing surgery for
idiopathic scoliosis37. Another study demonstrated a reduction in
intraoperative and postoperative blood loss, but not in allogeneic
blood transfusion, in patients treatedwith posterior spine fusion38.
Notably, in recent years aprotinin was associated with
concerns about increased risks of perioperative myocardial in-
farction, stroke, renal dysfunction39, and anaphylaxis. A recent
large-scale study involving 2331 patients showed that using
aprotinin in high-risk cardiac surgery was associated with higher
rates of mortality from cardiogenic shock, right ventricular fail-
ure, congestive heart failure, ormyocardial infarction40. Similarly,
aprotinin use in adults undergoing spine surgery to correct de-
formity may be associated with an increased risk of acute renal
failure and deep venous thrombosis41. The U.S. Food and Drug
Administration (FDA) suspended use, except for investigational
use, of aprotinin in late 2007.
Tranexamic Acid
Tranexamic acid is a synthetic lysine analogue that inhibits the
binding of lysine residues on fibrin to plasmin or plasminogen,
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thus preventing fibrinolysis. It has well-established efficacy in
reducing blood loss in knee and hip replacement surgery. In
contrast, the efficacy of tranexamic acid in reducing blood loss
in spine surgery has only recently been studied.
Shapiro et al.42 showed that tranexamic acid significantly
reduced (p < 0.001) both intraoperative blood loss and allo-
geneic blood transfusion requirements in spine fusions for
treatment of scoliosis in patients with Duchenne muscular
dystrophy. Elwatidy et al.43 found that the prophylactic use of
high-dose tranexamic acid was an effective, safe, and inexpen-
sive method for reducing blood loss during and after spine
operations. Wong et al.44 reported significantly reduced (p =
0.017) perioperative blood loss during elective posterior tho-
racic or lumbar spine fusion with instrumentation in adults.
Grant et al.45 showed that the efficacy of tranexamic acid is
dose-dependent. The use of a higher dose (a 20-mg/kg loading
dose followed by 10-mg/kg/hr intravenous infusion) for pa-
tients with idiopathic scoliosis resulted in a 50% reduction in
transfusion requirements compared with those associated with
a lower dose (10-mg/kg loading dose followed by a 1-mg/kg/hr
intravenous infusion).
Epsilon-Aminocaproic Acid
Epsilon-aminocaproic acid is another lysine analogue with
antifibrinolytic action. There are conflicting data regarding the
efficacy of epsilon-aminocaproic acid in reducing blood loss
during spine surgery. Florentino-Pineda et al.46 found a decrease
in blood loss and transfusion needs in patients undergoing
surgery for idiopathic scoliosis. Recently, Thompson et al. fur-
ther established the role of epsilon-aminocaproic acid in reduc-
ing blood loss and transfusion requirements in patient undergoing
anterior or posterior spine fusions for idiopathic scoliosis47 and
neuromuscular scoliosis47,48. However, other studies49-51 did not
show any benefit of epsilon-aminocaproic acid inmajor surgery,
including orthopaedic procedures.
Recombinant Factor VIIa
Recombinant factor VIIa improves hemostasis by enhancing
thrombin formation on activated platelets. It was approved
by the U.S. FDA for use in hemophilic patients with bleeding.
Off-label uses have been reported in operative settings such as
trauma surgery52-54, neurosurgery55,56, prostatic surgery57, car-
diac surgery58-61, and spine surgery62. Two recent studies showed
promising results in terms of reducing blood loss and alloge-
neic blood transfusion during spine surgery. The first was a
retrospective case series of adolescents with idiopathic scolio-
sis63, and the second was a prospective randomized controlled
trial64. Although the authors of the randomized controlled trial
claimed that ‘‘no safety concerns were indicated for the use of
rFVIIa in patients at all doses tested,’’ the study may be un-
derpowered to address such concerns. Moreover, there was one
case of myocardial infarction and one case of ischemic stroke in
the group that received recombinant factor VIIa in this study,
findings that warrant further investigation.
A retrospective review showed that when 15 to 180 mg/kg
of recombinant factor VIIa was administered to patients with
bleeding due to a coagulopathy in medical and surgical set-
tings, 80% (thirty-two of forty) had complete or partial ces-
sation of the bleeding65. Another study showed that cessation
of bleeding was not significantly different among doses of
<70 mg/kg, 70 to 90 mg/kg, and >90 mg/kg66. Thus, the current
recommended dose of recombinant factor VIIa is about 70 to
90 mg/kg.
We do not advocate the off-label use of any medication,
including recombinant factor VIIa. In addition, there are two
major concerns about the use of recombinant factor VIIa:
thrombotic complications and its cost. The risk of thrombotic
events with approved uses of recombinant factor VIIa is low67,
but thrombotic stroke, myocardial infarction, deep vein throm-
bosis, andmortality have all been reported in associationwith off-
label use of the drug, including in patients undergoing spine
surgery64. The cost of a single dose of 90 mg/kg in a 70-kg adult is
over $5000.
Desmopressin
Desmopressin, also known as DDAVP, is a synthetic analogue
of the antidiuretic hormone vasopressin. It increases the levels
of factor VIII and vonWillebrand factor and is indicated for use
in von Willebrand disease, platelet disorders, or platelet dys-
function in patients with cirrhosis or renal failure68. Its use in
spine surgery to decrease intraoperative blood loss has been
reported, but a definite benefit has not yet been established.
A controlled trial69 showed desmopressin use to be associated
with a decrease in blood loss and transfusion requirements in
scoliosis surgery. However, a considerable number of other studies
did not show a reduction of blood loss in patients undergoing
surgery for idiopathic, congenital, or neuromuscular scoliosis70-72.
The authors of one study reported that there was no evidence to
support the routine use of desmopressin in orthopaedic surgery 50.
Use of Intrathecal Morphine
A meta-analysis by Guay73 showed that neuraxial blocks (epi-
dural or spinal) in addition to general anesthesia or as the sole
anesthetic technique decrease intraoperative and postoperative
blood loss as well as the need for transfusion associated with
different types of operative interventions, including spine fu-
sion. The use of local anesthetics in neuraxial blocks causes
hypotension, which is generally believed to cause the reduction
in blood loss associated with neuraxial blocks. The use of local-
anesthetic-based neuraxial blocks in major spine surgery may
be undesirable because of the associated hypotension, which
may aggravate hemodynamic instability should major bleeding
occur, as well as because of concerns about hypotension in a
patient in a prone position. In addition, the use of local anes-
thetic neuraxial blocks may make neurological assessment more
difficult postoperatively.
Unlike local anesthetics, neuraxial opioids such as in-
trathecal morphine do not interfere with neurological assess-
ment and they cause less hypotension. Intrathecal morphine
reduces blood loss in major spine surgery, in addition to pro-
viding satisfactory pain relief. In at least three prospective
randomized trials, intrathecal morphine administered before
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operations substantially reduced intraoperative blood loss.
Goodarzi74 used 0.02 mg/kg of intrathecal morphine together
with 50 mg of sufentanil and observed a 50% reduction in
blood loss. Gall et al.75 used 2 and 5 mg/kg of morphine and
observed a 65% reduction in blood loss in the 5-mg/kg group.
Eschertzhuber et al.76 showed that intrathecal morphine (either
5 or 15 mg/kg, plus 1 mg/kg of sufentanil) reduced blood loss
by 48%. Despite the consistent efficacy, the mechanism for this
benefit remains elusive.
Use of Controlled Hypotension
Controlled hypotension has been used for decades in ortho-
paedic surgery to limit blood loss. Decreased blood extrava-
sation and local wound blood flow with lower arterial blood
pressure is the generally perceived benefit of this technique.
However, since epidural venous plexus pressure77 and intra-
osseous pressure78 are more important determinants of blood
loss in spine surgery in which bone decortications are involved,
and both are independent of arterial blood pressure, the exact
mechanism and value of this technique are still unknown.
Themain concernwith the use of controlled hypotension
is its potential complications. The most worrisome is postop-
erative loss of vision, which is estimated to occur in 0.09% of
patients (three of 3351 patients) undergoing spine surgery in
the prone position79. A long operative time, a prone position
with direct pressure to the eyes, massive blood loss, anemia,
and hemodilution are risk factors for loss of vision after spine
surgery. Hypotension is frequently observed in patients who
have postoperative loss of vision, although a definite associa-
tion remains to be established80. Induced hypotension must be
used extremely cautiously in patients undergoing surgery in the
prone position.
Low systolic blood pressure can also jeopardize perfusion
to end organs, including the spinal cord. Studies have shown
changes in the findings of evoked potential monitoring but
no increase in the rate of neurological deficits with controlled
hypotension81. Given the potential adverse effect of induced
hypotension on organ perfusion, the safety of induced hypo-
tension, particularly in combination with other techniques that
may also affect tissue oxygen delivery such as hemodilution,
requires proper evaluation.
Temperature Regulation
Hypothermia can lead to hemostatic impairment. Michelson
et al.82 found that the most important factor in the develop-
ment of hemostatic impairment is cold-induced impairment of
platelet function. Impaired enzyme activity in the coagulation
cascade plays only a minor role.
Mild hypothermia can increase blood loss and allogeneic
blood transfusion requirements during operative treatment.
Schmied et al. compared patients who had been randomized to
not receive active warming (mean core temperature, 35C) and
those who had been actively warmed (mean core temperature,
36.6C) during hip arthroplasty and found a 30% increase in
blood loss and a significant increase in blood transfusion re-
quirements (p < 0.05) in the former group83. Similarly, Winkler
et al. found a 26% increase in blood loss in patients undergoing
hip arthroplasty with a core temperature of 36.1C compared
with those aggressively warmed and with a core temperature of
36.5C84. The observation that such small differences in core
temperature were of importance is substantiated by a recent
meta-analysis85, which showed that a core temperature differ-
ence of <1C was associated with an average increase in blood
loss of 16% and an average increase in the risk of transfusion of
22% in all types of surgery, including hip arthroplasty, cardiac
surgery, major abdominal surgery, and hysterectomy.
No evidence regarding the use of temperature regulation
in spine surgery is available, to our knowledge. Moreover, a
retrospective review by Guest et al.86 showed that mild hypo-
thermia was not associated with any increase in blood loss
during spine surgery, although this was a small study involving
only seventy patients. Additional studies are required to con-
firm and explain this apparent discrepancy between spine sur-
gery and other surgical procedures.
Intraoperative Considerations
Patient Positioning
It is known that epidural veins are connected to the inferior
vena cava by a valveless venous system. In the prone position,
abdominal pressure increases and causes compression to the
vena cava, which in turn increases pressure in the epidural
venous circuit and increases intraoperative blood loss. In 1990,
Bo¨stman et al.87 demonstrated a significant reduction (p <
0.001) in intraoperative blood loss during lumbar spine surgery
in patients who had been placed on a frame in a supported
kneeling position with the abdomen free compared with pa-
tients lying on conventional bolsters. The investigators postu-
lated that this effect was brought about by a reduction in the
inferior vena caval pressure. This postulation was confirmed by
Lee et al.77. Those investigators studied differences in inferior
vena caval pressure between patients positioned in the tradi-
tional prone position on a conventional pad and those posi-
tioned on a Relton-Hall frame with the abdomen free from
compression. They found that vena caval pressure was signif-
icantly lower (p < 0.05) in the patients on the Relton-Hall frame.
More recently, Park88 found a correlation between reduction
in intra-abdominal pressure and reduction in intraoperative
blood loss in spine surgery. In their study, patients were ran-
domly assigned to lie on a Wilson frame with narrow or wide
pad support. The investigators found that both intra-abdominal
pressure (p < 0.05) and intraoperative blood loss (p < 0.05)
were significantly lower in the wide-pad-support group, in
which the patient’s abdomen was free from compression during
surgery. Total intraoperative blood loss was also found to be
highly correlated with the mean intra-abdominal pressure dur-
ing surgery.
Operative Techniques
The skin over the back, particularly over the neck region, is well
perfused. Blood oozing from the skin edge is common after a
surgical incision. This oozing can be minimized by local skin in-
filtration of 1:500,000 epinephrine. Nutrient vessels to paraspinal
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muscles are in close proximity to the vertebrae. Subperiosteal
dissection is essential to minimize damage to these vessels and
hence to reduce intraoperative bleeding89. Taking the proper
sequence of intraoperative steps can also help to reduce blood
loss. Spine fusions frequently require decortication of the
bone surfaces and lead to bone bleeding. Such bleeding can
be minimized by performing this part of the procedure last,
followed by the immediate creation of a tamponade of the
wound with rapid watertight wound closure. Careful oper-
ative hemostasis can reduce intraoperative and postoperative
blood loss. Soft-tissue bleeding can usually be stopped with
thermal coagulation. Bone bleeding can be stopped with a
small amount of bone wax. Epidural bleeding can usually
be controlled with bipolar diathermy. If the venous pres-
sure is low, applying hydrostatic pressure by just filling the
wound with saline solution may help control epidural ve-
nous bleeding90.
Use of Topical Hemostatic Agents
Despite all of the above techniques, bleeding can still be diffi-
cult to control. Various topical hemostatic agents are available
for use in these situations. They can be divided into two broad
categories: passive and active. Passive agents act through con-
tact activation and promotion of platelet aggregation. Active
agents generate a fibrin clot following activation of the clotting
cascade. Collagen-based, cellulose-based, and gelatin-based
hemostatic products are examples of passive topical hemostatic
agents. The basic mechanism of action is provision of a physical
structure that promotes platelet aggregation, leading to clot
formation and effective hemostasis91. Active agents have bio-
logical activity and directly participate at the end of the coag-
ulation cascade to induce the formation of a fibrin clot at
the site of bleeding. They include thrombin and combination
products containing thrombin and certain passive hemostatic
agents92,93. All have a rapid onset of action and provide hemo-
stasis within ten minutes in most patients91. As these agents are
directly involved in the final physiological events of the coag-
ulation cascade and bypass the initial enzymatic steps, their
hemostatic action is less susceptible to coagulopathies caused
by clotting-factor deficiencies or platelet dysfunction.
Although topical hemostatic agents are effective in stop-
ping bleeding and reducing blood loss, they have potential dis-
advantages92. The expansion of a passive topical hemostatic agent
can result in complications, such as the compression of nerves in
surrounding tissue against bone or hard tissue with neurological
consequences. Any residual product at the site may also poten-
tiate a foreign-body reaction, chronic inflammation, or infection.
We recommend that only the minimum amount of hemostatic
agent necessary to achieve hemostasis be used and that as much
of the agent as possible be removed once hemostasis has been
achieved.
Minimally Invasive Spine Surgery
Intraoperative blood loss can be minimized by the use of less
invasive operative approaches, such as paraspinalmuscle-splitting,
endoscopic, and percutaneous instrumentation techniques. In
contrast tomidline subperiosteal dissection andmuscle retraction
to gain access to the spinal canal, micro-endoscopic lumbar
discectomy, with a direct approach to the herniated disc frag-
ment under intraoperative fluoroscopic guidance and a muscle-
splitting technique, has been shown to produce a smaller surgical
wound, less postoperative wound pain, and less intraoperative
blood loss. Huang et al.94 and Ryang et al.95 demonstrated that
lumbar discectomies performed with a micro-endoscopic tech-
nique are associated with a 50% reduction in intraoperative
blood loss compared with that associated with standard open
discectomies. Lumbar spine fusion can also be performed with
minimally invasive techniques. These include a paraspinalmuscle-
splitting approach and performance of percutaneous instrumen-
tation under fluoroscopic control. Compared with conventional
open procedures, which involve wide posterior exposure from the
midline to the tips of the transverse processes and freehand ap-
plication of instrumentation, minimally invasive techniques can
markedly reduce intraoperative blood loss. Rodrı´guez-Vela et al.96
compared one-level lumbar spine fusion performed with a min-
imally invasive technique with that performed with a standard
open technique. Intraoperative blood loss was 757 mL in the
group treatedwith the standard open technique and 318mL in the
group treated with the mini-open procedure. Park and Ha re-
ported similar findings, with intraoperative blood loss of 738 mL
in a group treated with a standard open procedure compared
with 433 mL in a group treated with a minimally invasive
technique97. The difference in blood loss between minimally
invasive surgery and a conventional open procedure is even
greater in multiple-level spine fusions. Anand et al. reported an
average intraoperative blood loss of only 260 mL in their series
in which minimally invasive multiple-level percutaneous cor-
rection and fusion had been performed for adult lumbar de-
generative scoliosis98; this compares with a blood loss of 1 to 3 L
with open procedures99.
Minimally invasive techniques are not without disad-
vantages. With the endoscopic approach, operative dissection is
performed via a two-dimensional, small visual field. Percep-
tions of anatomy and depth are more difficult compared with
those with open procedures. Furthermore, minimally invasive
techniques frequently require special long instruments that are
passed through the working portals to gain access to the op-
erative sites. All of these characteristics make minimally inva-
sive surgery technically more demanding andmay lead to higher
surgical complication rates, especially in inexperienced hands.
Nowitzke100 reported his early experience withmicro-endoscopic
discectomy. He estimated that he needed to perform thirty pro-
cedures to learn the technique to perform the operation profi-
ciently, and he encountered seven complications, including dural
tears and wrong-level surgery.
Postoperative Period
Postoperative Red-Blood-Cell Salvage
There have been few studies on postoperative blood salvage
after spine surgery20,21,101. Because postoperative salvage was com-
bined with other techniques in earlier studies, it was impossible to
evaluate the effect of this technique. Sebastia´n et al.101 evaluated
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postoperative salvage only and found that it reduced the allo-
geneic blood requirement by 30%. Although the reinfusion of
unwashed postoperatively collected blood has been criticized
for introducing harmful substances such as cell debris, marrow
fat, fibrin, and free hemoglobin, the use of standard 40-mm
blood filters for infusion of recovered blood has solved this
potential problem102-104. Unlike intraoperative salvage, post-
operative salvage has not been evaluated in terms of its cost-
effectiveness.
General Considerations
Indications for Transfusion
In recent years, there has been a general paradigm shift toward
many surgeons and anesthesiologists adopting more restrictive
indications for red blood-cell transfusion, although whether
this has had any significant impact on the reduction of allo-
geneic blood usage remains controversial105. The proof-of-
concept Canadian Transfusion Requirements in Critical Care
(TRICC) study106, which compared a more restrictive threshold
for transfusion (a hemoglobin level of 7 g/dL) with a more
liberal threshold (10 g/dL) showed no significant difference in
overall mortality between the two groups. The same group of
investigators found similar results in children107. A recent sys-
tematic review108 showed that, in forty-two of forty-five studies,
the risks of red blood-cell transfusion outweighed the benefits,
the risk was neutral in two studies, and the benefits outweighed
the risks in a subgroup (elderly patients with an acute myo-
cardial infarction and a hematocrit of <30%) of a single study.
On the basis of the results of these studies and others,
evidence-based practice guidelines and recommendation state-
ments on red blood-cell transfusion were developed and have
been constantly updated by relevant associations and societies.
For instance, the Association of Anaesthetists of Great Britain
and Ireland (AAGBI) stated that a hemoglobin concentration of
<7 g/dL is a ‘‘strong indication for [red-blood-cell] transfusion’’
while transfusion is not required when the hemoglobin con-
centration is >10 g/dL109. Similarly, the American Society of
Anesthesiologists Practice Guidelines recommended that ‘‘red
blood cells should usually be administeredwhen the hemoglobin
level is less than 6 g/dl’’ and ‘‘strongly agree that red blood cells
are usually unnecessary when the level is more than 10 g/dl.’’110
The determination of whether intermediate hemoglobin con-
centrations (i.e., 6 to 10 g/dL) justify or require red blood-cell
transfusion should be based on the patient’s risk for complica-
tions of inadequate oxygenation. Moreover, the indications for
transfusion of autologous red blood cells may be more liberal
than those for transfusion of allogeneic red blood cells because
the former is associated with less frequent (although still im-
portant) risks.
Although the most desirable transfusion threshold for
patients undergoing spine surgery has not been specifically
studied, the more general guideline of performing a transfusion
when the hemoglobin concentration is <7 g/dL and of carefully
weighing the risks against the benefits when the hemoglobin
concentration is between 7 and 10 g/dL should apply to most
patients.
Use of Combination of Techniques
Many of the techniques and concepts discussed above can be
conveniently combined in the perioperative period. However,
although there have been small-scale studies in which more
than one technique was employed13,19,20, whether such combi-
nations are desirable has not been properly evaluated and re-
mains unknown. Safety is the most important concern. For
instance, the risk factors for postoperative loss of vision when
an operation in performed with the patient in the prone po-
sition include both hypotension and hemodilution. Therefore,
caution should be exercised before combining induced hypo-
tension with a lower tolerance for transfusion. Even when the
patient is not in the prone position, it is conceivable that the
safety of these techniques individually may not be extrapolated
to the situation when the techniques are combined, as tissue
oxygen delivery is described by the equation: cardiac output ·
hemoglobin concentration · oxygen saturation. Similarly, as
autologous predonation may lower preoperative hemoglobin
concentration, the advantage of combining this technique
with acute intraoperative hemodilution, or the advantage of one
over the other, is currently unknown. The marginal benefit of
combining different techniques, such as induced hypotension,
hemostatic drugs, and intrathecal morphine, is also unknown.
If it can be demonstrated that there is little marginal benefit in
adding a technique that tends to be associated with more severe
complications, such as induced hypotension, then this may
indicate a change in current practice. We could not find any
clinical studies that addressed these issues. Some of these tech-
niques do seem synergistic when combined. For instanceWaters
et al.111, using mathematical models, showed that the combi-
nation of intraoperative red-blood-cell salvage and acute nor-
movolemic hemodilution would allow more patients to avoid
allogeneic blood transfusion than would use of one or the other
individual technique alone.
Numerous techniques to reduce perioperative blood loss
and allogeneic blood transfusion during major spine surgery
have been investigated. In particular, many new studies have
provided data since the review by Szpalski et al.1 (see Appendix).
The effectiveness of many techniques remains to be proven by
large-scale randomized controlled trials. In particular, there is a
paucity of studies evaluating the safety and marginal benefit
of combining different techniques. Individually, intraoperative
acute normovolemic hemodilution, use of tranexamic acid, use
of intrathecal morphine, proper positioning, and modification
of operative techniques seem most promising. On the other
hand, additional studies are required to establish either the ef-
fectiveness or the safety of preoperative autologous predonation;
mandatory discontinuation of use of antiplatelet agents; intra-
operative and postoperative blood salvage; use of aprotinin, epsilon-
aminocaproic acid, recombinant factor VIIa, or desmopressin;
induced hypotension; avoidance of hypothermia; andminimally
invasive operative techniques.
Appendix
A table showing an evaluation of the latest studies
(published after 2004) on reducing perioperative blood
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loss and allogeneic blood transfusion in patients undergoing
major spine surgery is available with the online version of this
article at jbjs.org. n
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